Landscape Capital Management L.L.C. Takes $262,000 Position in Biodesix, Inc. (NASDAQ:BDSX)

Landscape Capital Management L.L.C. purchased a new stake in Biodesix, Inc. (NASDAQ:BDSX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 146,941 shares of the company’s stock, valued at approximately $262,000. Landscape Capital Management L.L.C. owned approximately 0.10% of Biodesix as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Perkins Capital Management Inc. increased its position in shares of Biodesix by 74.7% in the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after buying an additional 310,000 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Biodesix during the 2nd quarter worth about $3,326,000. CVI Holdings LLC purchased a new stake in Biodesix during the 2nd quarter worth about $59,000. Farallon Capital Management LLC purchased a new stake in Biodesix during the 2nd quarter worth about $2,874,000. Finally, AIGH Capital Management LLC increased its position in Biodesix by 74.0% during the 2nd quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock worth $8,843,000 after purchasing an additional 2,458,727 shares in the last quarter. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Scotiabank began coverage on Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Biodesix presently has an average rating of “Buy” and an average target price of $3.06.

Biodesix Stock Up 3.9 %

BDSX opened at $1.33 on Tuesday. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. The stock has a market capitalization of $193.48 million, a price-to-earnings ratio of -3.41 and a beta of 1.22. The business has a 50-day moving average of $1.56 and a two-hundred day moving average of $1.61. Biodesix, Inc. has a 12 month low of $1.11 and a 12 month high of $2.21.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. During the same period in the previous year, the company posted ($0.12) EPS. On average, research analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Insider Activity

In other news, Director Matthew Strobeck acquired 40,000 shares of Biodesix stock in a transaction dated Tuesday, November 5th. The shares were acquired at an average cost of $1.40 per share, with a total value of $56,000.00. Following the purchase, the director now directly owns 2,606,879 shares of the company’s stock, valued at approximately $3,649,630.60. This trade represents a 1.56 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman John Patience purchased 75,000 shares of Biodesix stock in a transaction that occurred on Tuesday, November 5th. The shares were bought at an average cost of $1.38 per share, for a total transaction of $103,500.00. Following the completion of the transaction, the chairman now directly owns 2,153,298 shares in the company, valued at $2,971,551.24. This represents a 3.61 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 315,000 shares of company stock valued at $393,500 in the last three months. Corporate insiders own 69.20% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.